2. Search Result
Search Result
Isoforms Recommended: STAT6
Results for "

STAT6

" in MedChemExpress (MCE) Product Catalog:

65

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

1

Peptides

2

Inhibitory Antibodies

12

Natural
Products

4

Recombinant Proteins

6

Antibodies

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100614
    AS1517499
    Maximum Cited Publications
    47 Publications Verification

    		 STAT Inflammation/Immunology Cancer
    AS1517499 is a potent and brain-permeable STAT6 phosphorylation inhibitor with an IC50 of 21 nM.
    AS1517499
  • HY-169179
    AK-1690

    		PROTACs STAT Cancer
    AK-1690 is a selective PROTAC degrader targeting STAT6 (DC50=1 nM) with a Ki of 6 nM against human STAT6. AK-1690 degrades STAT6 via the interaction of STAT6 with cereblon and a ubiquitin-like process. AK-1690 effectively depletes STAT6 protein in mouse liver and lung tissues, and is applicable to research related to leukemia, Hodgkin's lymphoma, follicular lymphoma, etc. .
    AK-1690
  • HY-113402
    Gamma-glutamylcysteine
    4 Publications Verification

    γ-Glu-Cys

    		 Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease [6] .
    Gamma-glutamylcysteine
  • HY-148096
    STAT6-IN-1
    1 Publications Verification

    		 STAT Inflammation/Immunology Cancer
    STAT6-IN-1 (Compound 19a) is a STAT6 inhibitor with a high affinity for the SH2 domain of STAT6 (IC50=0.028 µM). STAT6-IN-1 can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer .
    STAT6-IN-1
  • HY-177456
    STAT6 degrader-3

    		STAT Inflammation/Immunology
    STAT6 degrader-3 (Compound I-1) is a potent and selective STAT6 degrader with a DC50 of <1 nM. STAT6 degrader-3 can be used in the research of Type 2 immune and allergic responses .
    STAT6 degrader-3
  • HY-153992
    STAT6-IN-3
    1 Publications Verification

    		 STAT Inflammation/Immunology
    STAT6-IN-3 is a phosphopeptide mimic targeting the SH2 domain of STAT6 and has a high affinity for STAT6 (IC50: 0.04 μM). STAT6-IN-3 can be used in the research of inflammation such as asthma .
    STAT6-IN-3
  • HY-176857
    PROTAC STAT6 degrader-1

    		PROTACs STAT Inflammation/Immunology Cancer
    PROTAC STAT6 degrader-1 (Compound I-2) is a potent STAT6 PROTAC degrader with a DC50 <1 nM. PROTAC STAT6 degrader-1 inhibits STAT6 activity with an IC50 of <0.1 pM. PROTAC STAT6 degrader-1 can be used for inflammatory and cancers research, such as non-small cell lung cancer (NSCLC) .
    PROTAC STAT6 degrader-1
  • HY-158398
    STAT6-IN-4

    		STAT Inflammation/Immunology
    STAT6-IN-4 (Ex. 78) is a STAT6 inhibitor, with an IC50 of 0.34 μM. STAT6-IN-4 can be used in the research of diseases such as inflammatory and allergic diseases .
    STAT6-IN-4
  • HY-N2609
    7,4'-Dihydroxyflavone
    4 Publications Verification

    		 COX CCR NF-κB Inflammation/Immunology Endocrinology
    7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC50=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production . 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC50 value of 1.4 µM .
    7,4'-Dihydroxyflavone
  • HY-169182
    AK-068

    		Ligands for Target Protein for PROTAC STAT Cancer
    AK-068 is a high-affinity and selective STAT6 ligand, with a Ki of 6 nM. AK-068 demonstrates at least >150- and >85-fold binding selectivity over STAT5A (Ki >1 μM) and STAT5B (Ki >500 μM) proteins, respectively. AK-068 is a ligand for target protein for PROTAC, can be used for synthesis of PROTACs .
    AK-068
  • HY-113402A
    Gamma-glutamylcysteine TFA
    4 Publications Verification

    γ-Glu-Cys TFA

    		 Interleukin Related TNF Receptor Endogenous Metabolite AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Gamma-glutamylcysteine TFA (γ-Glu-Cys TFA) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine TFA activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine TFA regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine TFA is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease [6] .
    Gamma-glutamylcysteine TFA
  • HY-158399
    STAT6-IN-5

    		STAT Inflammation/Immunology
    STAT6-IN-5 (compound 84) is a STAT6 inhibitor (IC50=0.24 μM), which can be used for the research of inflammatory diseases and allergic diseases (e.g. atopic dermatitis) .
    STAT6-IN-5
  • HY-N6985
    Baccatin III
    2 Publications Verification

    		 Others Cancer
    Baccatin III is an orally available, selective inhibitor of the TGF-β1 signaling pathway and myeloid-derived suppressor cell (MDSC) activation. Baccatin III targets the AKT/STAT6 and Smad2/3 pathways, blocking TGF-β1-induced fibroblast differentiation and MDSC-mediated immunosuppression. Baccatin III exerts anti-inflammatory and anti-fibrotic effects by inhibiting macrophage activation and extracellular matrix deposition, and shows potential in the treatment of pulmonary fibrosis and cancer in terms of regulating the tumor immune microenvironment .
    Baccatin III
  • HY-P990093
    Stapokibart

    CM310

    		 Interleukin Related STAT Inflammation/Immunology
    Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively). Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) .
    Stapokibart
  • HY-176949
    STAT6-IN-10

    		STAT Inflammation/Immunology
    STAT6-IN-10 is a STAT6 (signal transducer and activator of transcription 6) inhibitor with an EC50 of 2 nM. STAT6-IN-10 can inhibit the secretion of CCL17 in human peripheral whole blood. STAT6-IN-10 can be used in the research of dermatological and respiratory system diseases .
    STAT6-IN-10
  • HY-134772
    AS1810722

    		STAT Cytochrome P450 Inflammation/Immunology
    AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research .
    AS1810722
  • HY-176919
    PROTAC STAT6 degrader-3

    		PROTACs STAT Inflammation/Immunology Cancer
    PROTAC STAT6 degrader-3 is a potent STAT6 PROTAC degrader with a DC50 of less than 1 nM. PROTAC STAT6 degrader-3 can be used for research on allergic/inflammatory diseases and cancer .
    PROTAC STAT6 degrader-3
  • HY-134771
    YM-341619
    1 Publications Verification

    AS1617612

    		 STAT Inflammation/Immunology
    YM-341619 (AS1617612) is a potent and orally active STAT6 inhibitor with an IC50 of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 (IC50=0.28 nM) without affecting Th1 cell differentiation . YM-341619 is a promising compound for the the research of allergic diseases, such as allergic asthma .
    YM-341619
  • HY-162405
    STAT6-IN-12

    		STAT TGF-beta/Smad Interleukin Related Inflammation/Immunology
    STAT6-IN-12 is a potent STAT6 inhibitor with an IC50 of 50 nM. STAT6-IN-12 also inhibits Smad2/3 with an IC50 of 68 nM. STAT6-IN-12 inhibits TGFβ-dependent Smad2/3 signaling pathway, IL-4-dependent STAT6 signaling pathway, and cellular inflammatory responses. STAT6-IN-12 can be used for the research of inflammation .
    STAT6-IN-12
  • HY-153991
    STAT6-IN-2

    		STAT Inflammation/Immunology
    STAT6-IN-2 (Compound R-84) is a STAT6 inhibitor that can inhibit the tyrosine phosphorylation of STAT6. STAT6-IN-2 can also inhibit the secretion of eotaxin-3. STAT6-IN-2 can be used in the research of immune diseases and allergic inflammatory diseases such as asthma .
    STAT6-IN-2
  • HY-B1076
    Medrysone
    1 Publications Verification

    HMS; 6α-Methyl-11β-hydroxyprogesterone

    		 VEGFR CCR STAT Neurological Disease
    Medrysone (HMS; 6α-Methyl-11β-hydroxyprogesterone) is a STAT6 modulator and M2 macrophage polarization inducer. Medrysone enhances IL-4-triggered STAT6 activation, upregulates the expression of M2 markers, and promotes the secretion of VEGF and CCL2. Medrysone also enhances the pro-migratory activity of M2-like macrophages toward endothelial cells. By regulating macrophage polarization and related repair pathways, Medrysone significantly promotes corneal wound repair in a rat mechanical injury model. Medrysone can be used for research related to corneal injury .
    Medrysone
  • HY-169360
    SD-436

    		PROTACs STAT Cancer
    SD-436 is a highly selective and efficacious STAT3 PROTAC degrader (DC50: 0.5 μM), with IC50 of 19 nM (STAT3), 270 nM (STAT1), 360 nM (STAT4), >10 μM (STAT5) and >10 μM (STAT6). SD-436 promotes ubiquitination and degradation of STAT3, and induces tumor regression. SD-436 can be used for tumor research, such as leukemia and lymphoma (Pink: STAT3 ligand (HY-169361); Blue: E3 ligase ligand (HY-43722); Black: linker (HY-147052) .
    SD-436
  • HY-148092
    PM-43I

    		STAT Inflammation/Immunology Cancer
    PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research [1].
    PM-43I
  • HY-W1113771
    STAT6-IN-7

    		STAT Interleukin Related Inflammation/Immunology
    STAT6-IN-7 is a STAT6 inhibitor. STAT6-IN-7 exhibits an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. STAT6-IN-7 can be used in the research of atopic dermatitis .
    STAT6-IN-7
  • HY-116474
    Viridicatol

    		ERK JNK MMP p38 MAPK STAT Fungal Bacterial NO Synthase PGE synthase NF-κB Wnt β-catenin Infection Metabolic Disease Inflammation/Immunology
    Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .
    Viridicatol
  • HY-175650
    STAT6-IN-9

    		STAT Interleukin Related Inflammation/Immunology
    STAT6-IN-9 is a potent STAT6 inhibitor with an EC50 value of 4 nM. STAT6-IN-9 effectively blocks STAT6 activation mediated by the IL-13-IL-13 receptor/IL-4 receptor pathway. STAT6-IN-9 inhibits CCL17 secretion with an IC50 value of 4.6 nM. STAT6-IN-9 can be used to investigate various chronic inflammatory diseases mediated by STAT6, such as allergy, asthma, and chronic obstructive pulmonary disease .
    STAT6-IN-9
  • HY-N0566
    23-Hydroxybetulinic acid

    Anemosapogenin

    		 Apoptosis Autophagy Bcl-2 Family Caspase Survivin p38 MAPK MMP Cancer
    23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer [6] .
    23-Hydroxybetulinic acid
  • HY-148093
    PM-81I

    		STAT Inflammation/Immunology Cancer
    PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
    PM-81I
  • HY-176864
    STAT6 ligand-1

    		Ligands for Target Protein for PROTAC STAT Inflammation/Immunology Cancer
    STAT6 ligand-1 is a ligand for STAT6. STAT6 ligand-1 can be used for synthesizing PROTACs such as STAT6 degrader-2 (HY-176857) .
    STAT6 ligand-1
  • HY-179233
    PROTAC STAT6 degrader-2

    		PROTACs STAT Cancer
    PROTAC STAT6 degrader-2 is a highly efficient PROTAC degrader targeting STAT6. PROTAC STAT6 degrader-2 has a DC50 value of 1-10 nM for STAT6 in human PBMC cells and a DC50 value of less than 100 nM for STAT6 in HEK293-HIBiT-STAT6 cells. PROTAC STAT6 degrader-2 can be used for STAT6-mediated diseases .
    PROTAC STAT6 degrader-2
  • HY-P990090
    Rademikibart

    CBP-201

    		 Interleukin Related Inflammation/Immunology
    Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .
    Rademikibart
  • HY-172946
    SD-2301

    		PROTACs STAT Cancer
    SD-2301 is a selective STAT3 PROTAC degrader. SD-2301 induces STAT3 degradation without affecting the protein levels of other STAT family members (STAT1, STAT2, STAT4, STAT5, STAT6). SD-2301 exerts anti-tumor effects in B16F10-bearing mice. SD-2301 can be used for the study of cancer. (Pink: STAT3 ligand (HY-172947), Blue: VHL Ligand (HY-172948), Black: Linker (HY-W577012), VHL ligand-linker conjugate (HY-172949)) .
    SD-2301
  • HY-RS13896
    STAT6 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) STAT Others

    STAT6 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STAT6 Human Pre-designed siRNA Set A
    STAT6 Human Pre-designed siRNA Set A
  • HY-162404
    (14S,15R)-14-Deoxyoxacyclododecindione

    		STAT TGF-beta/Smad Interleukin Related TGF-β Receptor Inflammation/Immunology
    (14S,15R)-14-Deoxyoxacyclododecindione (Compound 3) acts as an inhibitor of TGF-β-dependent Smad2/3 and IL-4-dependent STAT6, with IC50 values of 90 nM and 20 nM, respectively. (14S,15R)-14-deoxyoxacyclododecindione is a potent IL-4 inhibitor with an IC50
    value of 20 nM. (14S,15R)-14-Deoxyoxacyclododecindione is applicable to the research of chronic inflammation and fibrotic diseases .
    (14S,15R)-14-Deoxyoxacyclododecindione
  • HY-161765
    iHSP110-33

    		HSP STAT Cancer
    iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
    iHSP110-33
  • HY-W1113770
    STAT6-IN-8

    		STAT Inflammation/Immunology
    STAT6-IN-8 (Compound 9) is a STAT6 inhibitor with potential anti-inflammatory and anti-allergic effects. STAT6-IN-8 can be used for the study of STAT6-associated diseases, including inflammatory diseases (atopic dermatitis, bronchial asthma) and allergic diseases (allergic rhinitis, chronic sinusitis) .
    STAT6-IN-8
  • HY-164216A
    (trans)-STAT6-IN-13

    		STAT Inflammation/Immunology Cancer
    (trans)-STAT6-IN-13 (Compound 95) is a STAT6 inhibitor with IC50 values of ≤300 nM. (trans)-STAT6-IN-13 has weak inhibitory for STAT3. (trans)-STAT6-IN-13 can be used for the researches of cancer, inflammation and immunology .
    (trans)-STAT6-IN-13
  • HY-113509B
    15(R)-Lipoxin A4

    15-epi-LXA4

    		 STAT COX Lipoxygenase JNK Endogenous Metabolite Neurological Disease Inflammation/Immunology
    15 (R)-Lipoxin A4 (15-epi-LXA4) is a specialized pro-resolving mediator and an acetylated derivative of COX2. 15 (R)-Lipoxin A4 is present in neurons. 15 (R)-Lipoxin A4 induces the SPM synthases ALOX12 and ALOX15, as well as the pro-resolving receptor ALX. 15 (R)-Lipoxin A4 inhibits protein kinases, including JNK1/2/3, Lyn, STAT-3 and STAT-6. 15 (R)-Lipoxin A4 enhances the release of pro-resolving mediators. 15 (R)-Lipoxin A4 alleviates the pro-inflammatory phenotype of tendon-derived stromal cells. 15 (R)-Lipoxin A4 promotes the resolution of neuroinflammation. 15 (R)-Lipoxin A4 is applicable to research related to achilles tendinitis, achilles tendon rupture and Alzheimer’s disease .
    15(R)-Lipoxin A4
  • HY-125019
    iJak-381

    		JAK STAT Inflammation/Immunology
    iJak-381 is a JAK1/2 inhibitor with anti-inflammatory activity. iJak-381 blocks IL-13 signaling and also inhibits IL-4 and IL-6 signaling pathways. iJak-381 also reduced p-STAT6 levels and inhibited the influx of inflammatory cells into the lungs of mice. iJak-381 inhibits airway hyperresponsiveness (AHR) .
    iJak-381
  • HY-167692
    JI069

    		STAT Others
    JI069 is a novel JAK-STAT inhibitor that demonstrates potent activity in suppressing Th1, Th2, and Th17 differentiation while promoting iTreg differentiation. JI069 effectively inhibits STAT3 activation as well as the activation of other STATs, including STAT1, STAT5, and STAT6. JI069 has shown significant therapeutic potential in alleviating symptoms of collagen-induced arthritis in mice while inhibiting cytokine production from T cells and the phosphorylation of STAT3 in synovial cells.
    JI069
  • HY-113402R
    Gamma-glutamylcysteine (Standard)

    γ-Glu-Cys (Standard)

    		 Reference Standards Endogenous Metabolite Interleukin Related TNF Receptor AMPK Sirtuin STAT PI3K NF-κB JAK p38 MAPK JNK Akt Apoptosis Ferroptosis Inflammation/Immunology
    Gamma-glutamylcysteine (Standard) is the analytical standard of Gamma-glutamylcysteine. This product is intended for research and analytical applications. Gamma-glutamylcysteine (γ-Glu-Cys) is an orally active, blood-brain barrier permeable dipeptide . Gamma-glutamylcysteine activates AMPK, SIRT1, IL-4/STAT6, AC/cAMP/PI3K, IGF-1R/IRS1/PI3K, and Nrf2 signaling pathways; it inhibits NF-κB, JAK1/STAT1/3, MAPKs, cadmium-induced p38 MAPK, JNK, and PI3K/Akt signaling pathways. Gamma-glutamylcysteine regulates macrophage polarization, modulates the trafficking of CD36 and GLUT4, induces glutathione synthesis, improves metabolic dysfunction, reduces lipid deposition, ameliorates glucose homeostasis, inhibits apoptosis (Apoptosis), stabilizes mitochondria, suppresses lipid peroxidation, iron accumulation and ferroptosis (Ferroptosis), reduces ds-HMGB1 levels, reverses mechanical hyperalgesia, and alleviates hepatic lipid droplet formation. Gamma-glutamylcysteine is applicable to research related to inflammatory bowel disease, type 2 diabetes, cadmium-induced neurotoxicity, Alzheimer's disease, cerebral ischemia/reperfusion injury, neuropathy, and alcoholic liver disease.
    Gamma-glutamylcysteine (Standard)
  • HY-RS13897
    Stat6 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) STAT Others

    Stat6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat6 Mouse Pre-designed siRNA Set A
    Stat6 Mouse Pre-designed siRNA Set A
  • HY-RS13898
    Stat6 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Stat6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat6 Rat Pre-designed siRNA Set A
    Stat6 Rat Pre-designed siRNA Set A
  • HY-164177
    STAT6 modulator-3

    		STAT Inflammation/Immunology Cancer
    STAT6 modulator-3 (compound 37) is a STAT6 modulator with an IC50 value less than 300 nM. STAT6 modulator-3 can be used in the research of cancer and inflammatory .
    STAT6 modulator-3
  • HY-171441
    STAT6 degrader-1

    		STAT Inflammation/Immunology Cancer
    STAT6 degrader-1 (Compound 21) is a bifunctional molecular glue degrader of STAT6 that recruits E3 ubiquitin ligase. STAT6 degrader-1 induces proteasomal degradation of STAT6. STAT6 degrader-1 is applicable to the research of cancer, inflammatory diseases and colorectal cancer .
    STAT6 degrader-1
  • HY-181901
    PROTAC STAT6 degrader-4

    		PROTACs STAT Inflammation/Immunology
    PROTAC STAT6 degrader-4 (Compound 3u247) is a STAT6 PROTAC degrader with a DC50 of 0.04 nM. PROTAC STAT6 degrader-4 promotes the ubiquitination and degradation of STAT6, and is applicable to the research of immune diseases .
    PROTAC STAT6 degrader-4
  • HY-123115
    Leucrose

    5-O-α-D-Glucopyranosyl-D-fructose

    		 JAK STAT TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet .
    Leucrose
  • HY-180475
    STAT6 ligand-2

    		Ligands for Target Protein for PROTAC STAT Cancer
    STAT6 ligand-1 is a ligand of STAT6. STAT6 ligand-1 can be used to synthesize PROTACs, such as Compound 22 .
    STAT6 ligand-2
  • HY-183733
    STAT6 degrader-4

    		STAT Cancer
    STAT6 degrader-4 (Compound I-677) is a STAT6 degrading agent with a DC50 of less than 1 nM. STAT6 degrader-4 can be used in cancer research.
    STAT6 degrader-4
  • HY-164203
    STAT6-IN-6

    		STAT Cancer
    STAT6-IN-6 (compound 163) is a selective STAT6 inhibitor. STAT6-IN-6 selectively inhibits STAT6 phosphorylation, with IC50s of ≤100nM and >3μM for pSTAT6 and pSTAT3, respectively. STAT6-IN-6 can be used for the study of cancer and inflammatory diseases .
    STAT6-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: